Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport RU Dose-Ranging Study for Glabellar Lines
NCT01333397Phase 2Completed
- Sponsor
- Ipsen
- Start
- Mar 2011
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of abobotulinumtoxinA in glabellar lines, sponsored by Ipsen. Started Mar 2011; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT01333397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333397.